Remote Senior Director, GPO, Corporate Accounts & Strategic Partnerships at Kuraoncology
Kuraoncology · Boston, San Diego, Remote, United States Of America · Remote
Oyster – Hire globally with Oyster. Simplify payroll and compliance.
Sponsored by OysterAre you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.
At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.
As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality.
To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.
Essential Job Functions
Develop and execute a strategic account plan focused on GPO’s, Community Oncology and Strategic Access Partners. This individual will serve as the Oncology GPO and strategic partner expert for internal stakeholders. The role will lead strategy and tactics related to these strategic accounts while collaborating with marketing, medical, HEOR, legal, compliance, commercial operations, sales, and other members of the market access team to achieve corporate goals. This individual will work with the team to develop and deliver to key stakeholders a precommercial information exchange, value proposition, and GPO contracting strategy. The Senior Director will build relationships and develop strategies to improve patient access and drive company performance within these customer segments. This individual develops and ensures execution of the account business plans, which include both strategic and financial objectives. This individual will develop strong access and business relationships and communicate with national oncology decision makers and advisors within a variety of accounts. Combines knowledge of the healthcare and biotech industries with evolving payer trends, competitors’ strategies, customer business models, legislative/political environment, and insightful financial analysis into the development of Kura Oncology strategy. The Senior Director role will manage GPO contracts, service contracts, evaluate operational efficiency and effectiveness of our strategies while troubleshooting issues as they arise and identifying ongoing opportunities for improved executional excellence.
Responsibilities:
- Develop and execute a strategic business plan for Oncology National Accounts and strategic partners
- Support development of GPO contracting strategy in collaboration with Head of Patient Services and Trade, pricing committee and commercial leadership
- Interface with cross-functional leadership to communicate and align on Market Access and Oncology National Accounts strategies
- Set up and negotiate MSA, GPO contracts, data, service contracts with partners ensuring that targeted market penetration, product availability, revenue margin and patient needs are met
- Collaborate with internal stakeholders and cross functional team members, including medical affairs, marketing, sales, legal, finance, market access, operations as well as external consultants and vendors
- Collaborate with internal cross functional team and external vendors to develop precommercial information exchange presentation and present to key external decision makers at GPO’s, IDN’s, and Strategic Partners
- Proactively manage GPO and IDN access through engagement with key stakeholders, including access influencers, to ensure patient access and anticipate and mitigate potential challenges within each national network. US Oncology, One Oncology, AON, Athena, ION, etc.
- Partner with Medical Affairs and HEOR lead to ensure Kura products are placed on provider network clinical pathways (USO Value pathways), IDN pathways and formularies
- Establish direct relationships with C-Suite, E-Suite, Medical Directors and key decision makers within each Strategic Account
- Manage the corporate relationship with Access Strategic partners (i.e. COA, NCCN, NCODA)
- Lead interactions and engagements with GPO networks, market access strategic partners through advisory boards, congresses, and network meetings
- Collaborate with Kura internal stakeholders to ensure alignment with Launch Readiness Reviews and pre commercial planning meetings
- Serve as a team member as required at pricing committee, launch/commercialization planning, value and real-world evidence, integrated strategic planning, and brand planning
Job Requirements
- Bachelor’s degree in relevant field of study; MBA preferred
- Minimum 10 years of National Account management experience with GPO’s and strategic partners (e.g. ION, McKesson/Ontada, US Oncology, NCODA, COA, Cardinal Specialty Solutions.)
- Current relationships with key oncology GPO, IDN, and Strategic partner stakeholders
- Oral oncology product launch experience required. Launch experience on behalf of a publicly traded company’s first oncology/hematology market entry preferred.
- Experience with contract development, negotiation, implementation, execution and performance monitoring.
- Strong presentation skills
- Experience working with cross-functional teams in developing and executing strategic business plans supported through strong interpersonal and communication skills.
- Strategic Thinking & Problem Solving - Make decisions considering the long-term impact to patients and strategic partners.
- Ability to interact effectively with and influence senior leadership, peers and other cross functional team members.
- Extensive understanding of the business of oncology, previous start up experience and clinical knowledge and data for launch product and competition.
- Patient & Customer Centricity - Maintain an ongoing focus on the needs of our customers and/or key stakeholders.
Kura’s Values that are used for candidate selection and performance assessments:
- We work as one for patients
- We are goal-focused and deliver with excellence
- We are science-driven courageous innovators
- We strive to bring out the best in each other and ourselves
The Kura Package
- Career advancement/ development opportunities
- Competitive comp package
- Bonus
- 401K + Employer contributions
- Generous stock options
- ESPP Plan
- 20 days of PTO to start
- 18 Holidays (Including Summer & Winter Break)
- Generous Benefits Package with a variety of plans available with a substantial employer match
- Paid Paternity/Maternity Leave
- In-Office Catered lunches
- Home Office Setup
- Lifestyle Spending Stipend
- Commuter Stipend (Boston Office)
- Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more!
Kura Oncology is a clinical-stage biopharmaceutical company discovering and developing personalized therapeutics for the treatment of blood cancers and solid tumors. The company’s diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s approach to drug development is focused on rapidly translating novel science into life-saving medicines. Our goal is to help patients with cancer lead better, longer lives. Kura Oncology has offices in San Diego, California, and Boston, Massachusetts.
Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of R/R NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.
Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.
